First in man: transcatheter, transapical double valve replacement
Sprache des Titels:
Transcatheter aortic valve replacement is a well-established therapy for severe aortic stenosis (AS) in patients with high surgical risk. Transcatheter mitral valve replacement just recently emerged as a novel modality to treat severe mitral regurgitation (MR). We present the first case of a transcatheter, transapical native double valve replacement for severe AS and MR. Our case shows that it is a safe and effective method, not requiring cardiopulmonary bypass and drastically reducing the procedural time. Therefore, patients with significant comorbidities that portend a high surgical risk with poor long-term outcome may stand to benefit from this minimally invasive procedure.